



US 20100221742A1

(19) **United States**

(12) **Patent Application Publication**  
**Suri**

(10) **Pub. No.: US 2010/0221742 A1**

(43) **Pub. Date: Sep. 2, 2010**

(54) **NOVEL CANCER ASSOCIATED ANTIBODIES AND THEIR USE IN CANCER DIAGNOSIS**

(75) Inventor: **Anil Kumar Suri**, New Delhi (IN)

Correspondence Address:

**MERCHANT & GOULD PC**

**P.O. BOX 2903**

**MINNEAPOLIS, MN 55402-0903 (US)**

(73) Assignee: **NATIONAL INSTITUTE OF IMMUNOLOGY**, New Delhi (IN)

(21) Appl. No.: **12/705,117**

(22) Filed: **Feb. 12, 2010**

**Related U.S. Application Data**

(62) Division of application No. 11/664,881, filed on Oct. 30, 2007, filed as application No. PCT/IB2005/002972 on Oct. 7, 2005.

(30) **Foreign Application Priority Data**

Oct. 7, 2004 (IN) ..... 1945/DEL/2004

**Publication Classification**

(51) **Int. Cl.**  
**G01N 33/53** (2006.01)  
**C07K 16/32** (2006.01)

(52) **U.S. Cl.** ..... **435/7.1; 530/387.9; 530/387.3**

(57) **ABSTRACT**

The present invention relates to an antibody having specificity for a polypeptide comprising an amino acid sequence of SEQ ID No:2 or an isoform thereof or a polypeptide comprising SEQ ID NO:2.

Figure 1





Figure 2






Figure 3




Figure 4

## NOVEL CANCER ASSOCIATED ANTIBODIES AND THEIR USE IN CANCER DIAGNOSIS

[0001] This application is a Divisional of U.S. Ser. No. 11/664,881, filed 30 Oct. 2007, which is a National Stage of PCT/IB05/02972, filed 7 Oct. 2005, which claims benefit of Serial No. 1945/DEL/2004, filed 7 Oct. 2004 in India and which applications are incorporated herein by reference. To the extent appropriate, a claim of priority is made to each of the above disclosed applications.

### FIELD OF THE INVENTION

[0002] The present invention relates to novel cancer associated antibodies and antigens and their use in cancer diagnosis.

### BACKGROUND OF THE INVENTION

[0003] Cancer, as is known is a killer disease and is a subject of investigation and research by several workers in various countries. It is observed that in most cases, cancer is diagnosed and treated only in the advanced stage, when the cancer cells have already invaded and metastasized throughout the body. More than 60% of patients with breast, lung, colon and ovarian cancer already have hidden or overt metastatic colonies. At this stage, therapeutic modalities are limited in their success. Detecting cancers in early stages even in the premalignant state, means that current or future treatment modalities might have a higher likelihood of a true cure.

[0004] Ovarian cancer is a prime example of this clinical dilemma. More than two-thirds of cases of ovarian cancer are detected at an advanced stage, when the ovarian cancer cells have spread away from the ovary and have disseminated throughout the peritoneal cavity [Oure, A. O. Altorki, N. K. Stockert E, Scanlan MJ., Old L. J., & Chen Y. T. (1998) *Cancer Res* 58, 1034-1341]. Although the disease at this stage is advanced, it rarely produces specific or diagnostic symptoms. Consequently, ovarian cancer is usually treated when it is at an advanced stage. The resulting five year survival rate is 35-40% for late-stage patients who receive the best possible surgical and chemotherapeutic intervention.

[0005] By contrast, if ovarian cancer is detected when it is still confined to the ovary (stage I), conventional therapy produces a high rate (95%) of five-year survival. Hence, early detection of ovarian cancer lacks a specific symptom, a specific biomarker and accurate and reliable diagnostic, non-invasive modalities.

[0006] Traditional methods of treating cancer include use of non-invasive or mildly invasive diagnostic tests, biopsy, histological examination and so on. However, each of these tests have their own limitations and hence the search for new methods of diagnosis and treatment of cancer.

[0007] In keeping with the above, it is desirable to provide an effective, clinically useful biomarker measurable in a readily accessible body fluid and tissues. Clinical proteomics is well suited to discovery of such biomarkers, as serum is a protein-rich information reservoir that contains the traces of what has been encountered by the blood during its constant perfusion and percolation throughout the body.

[0008] However, until now, the search for cancer-related biomarkers for early disease detection has been a 'one-at-a-time' approach, which has looked for over-expressed proteins in blood that are shed into the circulation as a consequence of

the disease process [Adam, B. L., Vlahou, A., Semmes, O. J. & Wright, G. L. Jr. (2001) Proteomic approaches to biomarker discovery in prostate and bladder cancers. *Proteomics* 1, 1264-1270; Carter, D. et al. (2002) Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer, *Biochemistry* 41, 6714-6722; Rosty, C. et al (2002) Identification of hepatocarcinoma-intestine pancreas/pancreatitis-associated protein 1 as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. *Cancer Res.* 62, 2868-1875; Xiao, Z. et al. (2001) Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. *Cancer Res.* 61, 6029-6033; Kim, J. H. et al (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. *JAMA* 287, 1671-1679]. Thus, the art so far has provided markers that are tissue specific and assist in identification of a specific type of cancer. None of them serve as universal markers or have universal application.

[0009] Hence, there is a need in art to develop diagnostic agents that may be used as markers having universal application and thus useful for detection of any type of cancer. To fulfil this need, the invention provides novel antibodies against SEQ ID NO:2, its isoform or a polypeptide comprising SEQ ID NO:2 and its use in diagnosis of cancer.

### OBJECTS OF THE INVENTION

[0010] The main object of the invention is to provide a novel diagnostic agent useful for detection of cancer. Another object is to provide a kit and methods for detection of cancer.

### DESCRIPTION OF THE INVENTION

[0011] The inventor during some of their investigations had found a novel gene encoding sperm associated antigen 9 (SPAG9) [labelled herein as SEQ ID NO: 1] which has been cloned from human testis cDNA library. The 2523 by cDNA ([Shankar, Mohapatra and Suri (1998) *Biochem. Biophys. Res. Commun.* 243, 561-565; Acc. No: X91879] contains five direct repeats, three mirror repeats, three possible stem loop structures and three palindromic motifs. Open reading frame encodes a protein of 766 amino acids. The deduced protein analysis revealed several features: 1) a characteristic leucine zipper motif (LZ); 2) an extended coiled-coil domain (coil) and 3) a transmembrane domain (T). The amino acid sequence of SPAG9 (labelled herein as SEQ ID NO:2) further revealed that primary sequence identity to JNK binding domain. The secondary structural analysis revealed that SEQ ID NO:2 has an  $\alpha$ -helical structure. CD spectra analysis further supported a predominant  $\alpha$ -helical structure of SEQ ID NO:2. Microsequencing of oligomeric aggregates of recombinant SEQ ID NO:2 by tandem mass spectrometry confirmed the amino acid sequence and mono atomic mass to 83.9 kDa. The studies also revealed that SEQ ID NO:1 and 2 play a role in sperm-egg interaction. The said SEQ ID NO:1 was reported as a member of a new family of testis specific genes with a specific function and considered as a possible contraceptive target.

[0012] Thereafter, while the inventor was conducting certain unrelated studies on the MAPK (mitogen activated protein kinases pathway) and the involvement of proteins in this pathway, the inventor surprisingly found that SEQ ID NO:2 interacted with JNK signalling pathway. In fact, it had higher binding affinity to JNK3 and JNK2 compared with JNK1. No

interaction was observed with p38 $\alpha$  or ERK pathways. The said MAPK studies suggested that SEQ ID NO:2 molecule may be involved in cell-signalling pathway supporting cellular growth and cellular proliferation. This lead the inventor to investigate further the role of SEQ ID NO:2 in cancerous tissues as testis also involves a continuous proliferation of cells, almost mimicking the cancerous cell growth.

**[0013]** Surprisingly, the inventor found SEQ ID NO:1 nucleotide homology with various cancer tissue ESTs. In fact when tissue distribution of SEQ ID NO:1 was studied using different tissues, the inventors further found that mRNA of SEQ ID NO:1 is expressed exclusively in normal testis tissue. However, biological samples from various cancer patients revealed the presence of SEQ ID NO:2 in cancerous tissues such as lung, breast, stomach, uterus, esophagus, colon, ovarian, testis, cervix, skin, prostate, oral, bladder, endometrial, kidney, liver, brain, blood, vulva, vagina, gall bladder, eye and bone.

**[0014]** While not wishing to be bound by any theory, the inventor believes that SEQ ID NO:2 polypeptide peptide expressed in the aforesaid cancerous tissues may be recognized as a non-self protein by the immune system and may mount an auto-antibody response in such patients resulting in anti-SEQ ID NO:2 antibodies circulating in the blood stream of cancer patients. Such antibodies may provide a basis for early detection of cancer.

#### Anti-SEQ ID NO:2 Antibodies

**[0015]** Accordingly, in one aspect, the invention provides a novel antibody or an antigen-binding fragment thereof; having specificity for a polypeptide bearing SEQ ID No:2, or an isoform thereof or a polypeptide comprising the said SEQ ID NO:2. The said antibody may be an IgG antibody or IgM antibody or a single chain or a fragment of the said antibody having specificity to the said polypeptide of SEQ ID NO:2.

**[0016]** Such antibodies serve as markers as they appear to be found in subjects suffering from cancer. The said antibodies of the invention are termed as "anti-SEQ ID No:2 antibody" and referred to as such hereafter. The anti-SEQ ID No:2 antibody as referred includes the antigen-binding fragment thereof. The term "antibody", as used herein includes a polyclonal antibody, a monoclonal antibody, a humanized antibody and a single chain antibody.

**[0017]** The invention also provides a method for production of polyclonal anti-SEQ ID No:2 antibody comprising the steps of:

**[0018]** providing purified polypeptide of SEQ ID NO: 2 or synthesizing the same recombinantly by cloning and expressing SEQ ID NO:1 nucleic acid sequence in a suitable host;

**[0019]** mixing SEQ ID NO:2 with an adjuvant to obtain a composition,

**[0020]** injecting the composition into an animal to as produce an immune response, and

**[0021]** collecting the sera from the animal and isolating polyclonal antibody generated from the same.

**[0022]** In the method described above, the sera from the animal may be used directly or purified prior to use by various methods including affinity chromatography employing Protein A-Sepharose, antigen Sepharose or anti-mouse-Ig-Sepharose.

#### Antibody Detection Kit

**[0023]** In another aspect, the invention provides a kit useful for detection of cancer in a biological sample of a subject

suspected of or suffering from cancer. The said kit comprises a polypeptide sequence of SEQ ID NO:2 or an isoform thereof or a polypeptide comprising the said SEQ ID NO:2 as described herein above coupled to a solid matrix and instructional material. The solid matrix as referred herein may include nitrocellulose paper, glass slide, microtitre plates and wells.

**[0024]** In yet another aspect, the invention provides method for detecting a cancer in a subject suffering from or suspected of suffering from a cancer, comprising the steps of:

**[0025]** providing a biological sample of a subject suspected of cancer; and

**[0026]** detecting the presence of antibodies generated against SEQ ID NO:2 or an isoform thereof or a polypeptide comprising SEQ ID NO:2 in the sample, wherein presence of antibodies generated against SEQ ID NO:2 or an isoform thereof or a polypeptide comprising the said SEQ ID NO:2 is indicative of cancer.

**[0027]** In another aspect, the invention provides method for detecting a cancer in a subject suffering from or suspected of suffering from a cancer, comprising the steps of:

**[0028]** providing a biological sample of a subject suspected of cancer;

**[0029]** contacting the sample with the kit as set forth above and determining binding of SEQ ID NO:2 or an isoform thereof or a polypeptide comprising the said SEQ ID NO:2 with anti-SEQ ID No:2 antibody if present in biological sample through a detectable signal, which is indicative of cancer.

**[0030]** The detectable signal as referred herein may be any detectable signal such as development of color or fluorescence. For example, a secondary labelled antibody (enzyme conjugated antibody) may be introduced which may bind to anti-SEQ ID No:2 antibody if present in patient's sample and provide a detectable signal which may be used as a parameter for detection of cancer.

#### Antigen-Detection Kit

**[0031]** The antigen detection kit comprises an antibody having specificity to a polypeptide sequence bearing SEQ ID NO:2 or an isoform thereof or a polypeptide comprising SEQ ID NO:2. The kit is useful for detection of cancer.

**[0032]** In yet another aspect, the invention provides method for detecting a cancer in a subject suffering from or suspected of suffering from a cancer, comprising the steps of:

**[0033]** providing a biological tissue of a subject suspected of cancer; and

**[0034]** detecting the presence of sequence of SEQ ID NO:2 polypeptide or an isoform thereof or a polypeptide comprising SEQ ID NO:2 in the tissue, the presence of which is indicative of cancer.

**[0035]** In another aspect, the invention provides method for detecting a cancer in a subject suffering from or suspected of suffering from a cancer, comprising the steps of:

**[0036]** providing a biological tissue of a subject suspected of cancer;

**[0037]** contacting the tissue with the antigen-detecting kit as set forth above and determining binding of polypeptide sequence bearing SEQ ID NO:2[ or an isoform thereof or a polypeptide comprising SEQ ID NO:2] with anti-SEQ ID No:2 antibody through a detectable signal, which is indicative of cancer.

**[0038]** The detectable signal as referred herein may be any detectable signal such as development of color or fluores-

cence. For example, a secondary labelled antibody (enzyme conjugated antibody) may be introduced which may bind to the to the anti-SEQ ID No:2 antibody if present in patient's sample and provide a detectable signal which may be used as a parameter for detection of cancer. Yet another example is where the anti-SEQ ID No:2 antibody employed in the said kit may itself be a labelled antibody (labelled for color or fluorescence) and detectable signal produced may be used as a parameter for detection of cancer.

**[0039]** The term 'biological sample' as used herein refers to fluids or tissues obtained from subjects suspected of or suffering from cancer. Examples include blood, serum, plasma, tissue sample, urine and saliva. Further, 'cancer' as used herein refers to cancer of ectodermal, endodermal or mesodermal origin. The said cancer may be any cancer such as that of lung, breast, stomach, uterus, esophagus, colon, ovarian, testis, cervix, skin, prostate, oral, bladder, endometrial, kidney, liver, brain, blood, vulva, vagina, gall bladder, eye and bone. The 'subject' as referred above includes any mammal. A few embodiments of the invention are now illustrated by the following examples, and drawings:

#### BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS

**[0040]** FIG. 1 is a Dot Blot analysis comparing a control with patient's samples.

**[0041]** FIG. 2 which is a Western Blot analysis comparing a control with patient's samples.

**[0042]** FIG. 3 is the ELISA assay which indicates antibody titres in cancer patient's and healthy biological samples.

**[0043]** FIG. 4 represents the immunohistochemical analysis comparing the tissues obtained from normal healthy control and different cancer patients.

**[0044]** The examples below are meant for illustration only and are not intended as limitations on the inventive scope thereof. Various adaptations and variations that are possible in keeping with the inventive concept of the invention are deemed to fall within the scope of the invention.

#### EXAMPLE 1

##### Antibody Detection Kit

##### Preparation of Recombinant SEQ ID NO:2 Protein

**[0045]** The applicant conducted several studies based on the findings of the invention and have now identified the SEQ ID NO:2 polypeptide and which cloned in a suitable vector for large scale expression and purification as under:

##### Antigen Preparation: Plasmid Construction

**[0046]** Recombinant SEQ ID NO:2 protein (complete open reading frame encoding 766 amino acids) was successfully cloned in pET 28 b(+) expression vector. Briefly, a cDNA encoding a complete open reading frame of SEQ ID NO:1 was amplified using suitable primers. The product was digested with restriction enzymes and was inserted into digested pET28b(+) vector (Novagen, Madison, USA) containing multiple cloning sites to obtain pET28b- SEQ ID NO:2.

##### Expression of SEQ ID NO:2 Protein in *Escherichia coli*

**[0047]** Competent cells were prepared and transformed with pET28b- SEQ ID NO:2. Transformed cells were used to inoculate LB media for growing *E. coli* culture. Expression of

recombinant SEQ ID NO:2 was induced with IPTG (isopropyl-β-D-thiogalactopyranoside) and subsequently purified.

Purification of SEQ ID NO:2 Expressed in *Escherichia coli*

**[0048]** *E. coli* culture expressing SEQ ID NO:2 was harvested, washed and sonicated using sonication buffer containing urea. The sonicated sup was loaded on to the agarose beads column charged with nickel sulphate. The column was washed with washing buffers and elutes were collected using elution buffer. The purified SEQ ID NO:2 recombinant protein analysed for amino acid sequence by Mass Spectrometry. Amino acid sequencing analysis revealed that the recombinant SEQ ID NO:2 protein was expressed as deduced amino acid sequence published (EMBL Acc. No. 91879, Shankar et al., 1998).

##### Antibody-Detection Kit:

**[0049]** An antibody detection kit comprising SEQ ID NO:2 bound to a solid matrix is prepared as under:

**[0050]** A drop of purified SEQ ID NO:2 protein was placed on to the nitrocellulose membrane, fixed with methanol and air dried. The dipstick was dipped into transfer buffer and then air dried again. Dot blot analysis was performed by using dipsticks, which are made of polyester backing material with a nitrocellulose membrane.

**[0051]** To determine anti-SEQ ID No:2 antibody in the various biological samples from different cancer patients, the strip coated with SEQ ID NO:2 was dipped into the patient's biological fluid such as serum, followed by anti-human HRPO as secondary antibody (which was obtained from a commercial source). The dipstick was taken out and washed with PBS buffer. Finally, the strip was treated with 0.05% 3,3'-Diaminobenzidine (DAB) (Sigma).

**[0052]** In the dot blot analysis, the appearance of a dark brown reaction on nitrocellulose membrane indicated presence of anti-SEQ ID No:2 antibody in the sample. As compared to the samples obtained from cancer patients, the samples obtained from normal human subjects did not show any reaction. The results are shown in FIG. 1.

**[0053]** As shown in FIG. 1, biological samples from cancer patients exhibit strong reaction as compared to a healthy subject. Lane 1 represents the reaction with serum from normal subject—there is no development of any color. Lane 2 represents reaction with serum of cervix cancer, Lane 3 indicates reactivity of bladder cancer patient's serum, Lane 4 depicts the reaction of serum obtained from colon cancer patient, Lane 5 demonstrates the reaction of breast cancer serum, and Lane 6 is the reactivity of serum from ovarian cancer. Development of dark brown colour as in lanes 2 to 6 is indicative of cancer.

##### Gel Electrophoresis and Western Blotting

**[0054]** The presence of anti-SEQ ID No:2 antibodies in a biological sample may also be detected by western blotting procedure wherein recombinant protein is run on SDS PAGE and transferred onto nitrocellulose matrix:

**[0055]** Recombinant SEQ ID NO:2 protein was run on SDS polyacrylamide gel. Briefly, the protein solution was diluted with sample buffer. The samples were then loaded onto polyacrylamide gel. After electrophoresis, proteins were transferred onto nitrocellulose membrane. Blocked membrane was probed with cancer patients' serum and subsequently

with anti-human HRPO (which was obtained from a commercial source) as secondary antibody. Finally, strip was treated with 0.05% DAB.

**[0056]** Western blot analysis of sample of a patient suffering from cancer demonstrated a strong reactivity between cancerous sample and recombinant SEQ ID NO:2 protein. A strong band of recombinant SEQ ID NO:2 was observed on the nitrocellulose membrane strips treated with cancer patients' sample, whereas sample from normal human subjects failed to show any reactivity. The results are depicted in FIG. 2 which is a western blot analysis comparing a control with patient's samples. As shown in FIG. 2, lane 1 represents molecular weight marker, lane 2 represents sample obtained from normal person, lane 3 is the sample obtained from a subject with oral cancer, lane 4—bladder cancer, lane 5 lung cancer, lane 6 prostate cancer, lane 7 uterus, lane 8 ovary, lane 9 colon cancer and lane 10 breast cancer. As may be seen in the Western blot analysis, lanes 3 to 10 show presence of a band of 170 kDa which is absent in lane 2 of normal person.

Enzyme Linked Immunosorbent Assay (ELISA)

**[0057]** Further, the presence of anti-SPAG9 antibodies in a biological sample may also be detected by ELISA Technique as under:

**[0058]** Microtitration plates (Nunc, Rosaklide, Denmark) were coated with recombinant SEQ ID NO:2 protein for ELISA assay. Post blocking, the plates were incubated with the samples from cancer patients' and/or healthy control. Bound antibodies were revealed with anti-human immunoglobulins conjugated to horseradish peroxidase (which was obtained from a commercial source). Enzyme activation was carried out with 0.05% orthophenylenediamine as the substrate. The antibody response of cancer patients and healthy control individuals was represented as the mean of the absorbance of the sample of the individuals.

**[0059]** FIG. 3 is the ELISA assay which indicates antibody titres in cancer patient's and healthy biological samples. The absorbance values are indicated on Y-axis whereas different cancer types are depicted as numerals on the X-axis. (1) represents the titres obtained from serum samples from normal subject, (2) represents the titres obtained from cervix cancer patients, (3) denotes the titre values from patients suffering from bladder cancer, (4) gastrointestinal tract cancer, (5) ovarian cancer. The test sample titre values are considered indicative of cancer when the estimated ELISA titres are above the mean+2SD of healthy biological sample. Cancer patient's biological sample revealed higher ELISA titre values above the mean+2SD of healthy sample as indicated in the figure, which is indicative of cancer (+2SD is the standard cut off).

TABLE 1

Samples tested & Results:						
Biological sample	Dot blot analysis		Western blot analysis		ELISA	
	Normal	can-cerous	Normal	cancerous	Normal	cancerous
Lung	-	+	-	+	-	+
Breast	-	+	-	+	-	+
Prostrate	-	+	-	+	-	+
Bladder	-	+	-	+	-	+

TABLE 1-continued

Samples tested & Results:						
Biological sample	Dot blot analysis		Western blot analysis		ELISA	
	Normal	can-cerous	Normal	cancerous	Normal	cancerous
Utrous	-	+	-	+	-	+
Esophagus	-	+	-	+	-	+
Testis	-	+	-	+	-	+
Vulva	-	+	-	+	-	+
Liver	-	+	-	+	-	+
Eye	-	+	-	+	-	+
Oral	-	+	-	+	-	+
Kidney	-	+	-	+	-	+
Colon	-	+	-	+	-	+
Cervix	-	+	-	+	-	+
Vagina	-	+	-	+	-	+
Brain	-	+	-	+	-	+
Blood	-	+	-	+	-	+
Bone	-	+	-	+	-	+
Stomach	-	+	-	+	-	+
Ovarian	-	+	-	+	-	+
Skin	-	+	-	+	-	+
Gall bladder	-	+	-	+	-	+

EXAMPLE 2

Antigen Detection Kit

**[0060]** Preparation of Anti-SEQ ID No:2 Antibodies: Immunization of Rats with Recombinant SEQ ID NO:2 Protein

**[0061]** For generating anti-SEQ ID NO:2 antibodies, adult female rats were employed. Rats were immunized with SEQ ID NO:2 protein with a primary and two booster injections at different time intervals. First immunization of was done with SEQ ID NO:2 mixed with an adjuvant. Following booster injections were carried out at weekly intervals, rats are then bled and the sera isolated.

Purification of Anti-SEQ ID No:2 Antibodies from Rat Sera

**[0062]** The sera can be used directly or purified prior to use by various methods including affinity chromatography employing protein beads. Column containing protein A beads was loaded with rat sera and kept on the shaker for overnight. The column was centrifuged and flow through was collected. Subsequently, column was washed with binding buffer and finally elutes were collected after centrifugation. The concentration of antibodies was calculated by taking OD at 280 nm.

**[0063]** Thus the antigen detection kit was prepared comprising anti-SEQ ID No:2 antibodies, for detection of SEQ ID NO:2 protein in tissues: The details of the immunohistochemistry analysis performed is as below:

**[0064]** Tissues from cancerous patients were fixed by standard fixative using standard Immunohistochemistry procedure. Biological tissue sections were incubated with rat anti-SEQ ID No:2 antibody and then treated with goat anti-rat immunoglobulins conjugated to horseradish peroxidases (which was obtained from a commercial source). After washing, sections were treated with 0.01% DAB and were counterstained with Mayer's hematoxylin.

**[0065]** FIG. 4 represents the immunohistochemical analysis comparing the tissues obtained from normal healthy con-

trol and different cancer patients. The normal tissues are in the left lane while the cancerous tissues are depicted on right side.

**[0066]** (A) is the immunohistochemical analysis of cervix tissue obtained from normal subject, (A1) is the tissue obtained from subject suffering form cervix cancer; (B) is immunohistochemical analysis of normal mesenchymal tissue and (B1) is the tissue obtained from the subject suffering from mesenchymal cancer; (C) is the normal tongue tissue and (C1) is the tongue cancerous tissue; (D) is the normal skin tissue and (D1) is the skin cancerous tissue;

**[0067]** A strong reactivity between SEQ ID NO:2 and the anti-SEQ ID No:2 antibody was observed in cancer tissues whereas tissues from normal healthy controls did not reveal any reactivity. The development of brown color in the cancer tissues is indicative of cancer in the given subject.

Samples Tested:

**[0068]** Several cancerous tissues were examined for the expression of SEQ ID NO:2 protein and the results are set out below:

Tissue type	Antigen detection Kit	
	Normal	cancerous
Lung	-	+
Breast	-	+

-continued

Tissue type	Antigen detection Kit	
	Normal	cancerous
Prostrate	-	+
Bladder	-	+
Utreus	-	+
Esophagus	-	+
Testis	+	+
Vulva	-	+
Liver	-	+
Eye	-	+
Oral	-	+
Kidney	-	+
Colon	-	+
Cervix	-	+
Vagina	-	+
Brain	-	+
Blood	-	+
Bone	-	+
Stomach	-	+
Ovarian	-	+
Skin	-	+
Gall bladder	-	+

**[0069]** The strong reactivity of anti-SEQ ID No:2 antibodies with the cancerous tissues demonstrated the expression of SEQ ID NO:2 in various cancer cells. Since SEQ ID NO:2 is exclusively expressed in the normal testis, the presence of SEQ ID NO:2 in the tissues other than testis accounts for the onset/development of malignancy in the tissues.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 2

<210> SEQ ID NO 1

<211> LENGTH: 2523

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

gacaacttga gctgaaagcg aaaaactatg ctgaccagat tagcagactt gaagaaagag      60
aagcagaact gaagaaggaa tataatgcat tacatcaaag acacactgag atgatccata      120
attatatgga acatttagaa agaacaaaac ttcacagct ctcaggaggt gatcaactag      180
aatccacagc tcatagtaga attagaaaag aacgcctat atcattagga attttcccat      240
tacctgctgg agatggattg cttacacctg atgctcagaa aggaggagag acccctggat      300
ctgagcaatg gaaatttcag gaattaagtc aaccacgttc tcataccagc ctgaaggatg      360
agctttctga tgmttagcaa ggcggtacta aagetaccac tcagcatca acagctaatt      420
cagatgtggc aacaattcct actgatactc ccttaaagga agaaaacgaa ggatttgtga      480
aggttacaga tgcgccaat aaatcagaga taagcaaca cattgaagta caggtagccc      540
aggaaactag aaatgtatct actggctctg ctgaaaatga agaaaagtca gaagttcaag      600
caatcatcga atctactcct gagctggata tggacaaaga tctcagtgga tataaaggtt      660
caagcactcc caccaaagcg atagagaaca aagcttttga tcgcaataca gaatctctct      720
ttgaagaact gtcttcagct ggctcaggcc taataggaga tgtggatgaa ggagcagatt      780
    
```

-continued

---

```

tactaggaat gggctcgggaa gttgagaatc ttatattaga aaatacacia ctgttgaaa 840
ccaaaaatgc tttgaacata gtgaagaatg atttgatagc aaaagtggat gaactgacct 900
gtgagaaaga tgtgctgcaa ggggaattgg aggctgtgaa gcaagccaaa ctgaaactag 960
aggaaaagaa cagagaattg gaggaagagc ttaggaaagc tcgggcagaa gctgaagatg 1020
caaggcaaaa agcaaaagat gacgatgata gtgatattcc cacagcccag aggaaacggt 1080
ttactagagt agaaatggcc cgtgttctca tggagcgaaa ccagtataaa gagagattga 1140
tggagcttca ggaagctgtt cgatggacag agatgattcg ggcatcacga gaaaatccag 1200
ccatgcagga aaaaaaagg tcaagcattt ggagctttt cagccgactt tcagctcct 1260
caagtaacac gactaagaag cctgaaccac ctgttaactt gaagtacaat gcacctcag 1320
ctcatgttac tccgtccgtc aagaaaagaa gcagcacctt atctcagctc cctggggata 1380
agtccaaagc ctttgatttc cttagtgaag aaactgaagc tagtttagcc tcacgcagag 1440
aacaaaagag agagcagtat cgtcaggtaa aagcacatgt tcagaaggaa gacggtagag 1500
tgcaggcttt tggctggagt ctgcctcaga agtacaaca ggtaaccaat ggtcaagggtg 1560
aaaataagat gaaaaattta cctgtgcctg tctatctcag acctctggat aaaaaagata 1620
catcaatgaa gctgtgggtg cctgttggag tcaatttato tgggtgggaa accagagatg 1680
gtggttctgt tgttgagca agtgatattt acaaggatgt tegtgtttg gatcacagaag 1740
gcagtaaaaca gcgaagtgcc tctcagagta gtttagataa gttagatcag gaacttaagg 1800
aacagcagaa ggagttaaaa aatcaagaag aattatccag tctagtttgg atctgtacca 1860
gcaactcattc ggctacaaaa gttcttatta ttgatgctgt tcaacctggc aacatcctag 1920
acagtttcac tgtttgcaac tctcatgttc tgtgcattgc aagtggtcca ggtgcacgag 1980
aaacagacta cctgcagga gaagatcttt cagaatctgg tcaggtagac aaagcatctt 2040
tatgtggaag tatgacaagc aacagctcag cagagacaga cagcctgtta ggaggcatca 2100
cagtggttgg ttgttctgca gaaggtgtga cgggagctgc cacttcccct agtacaatg 2160
gtgcttctcc agtgatggat aaaccaccag aatggaagc agaaaatagt gaggttgatg 2220
aaaatgttcc aacagcagaa gaagcaactg aagctacaga agggaatgcg gggtcagctg 2280
aagacacagt ggacatctcc caaactggcg tctacacaga gcatgtcttt acagatcctt 2340
tgggagtcca gatcccagaa gacctctccc cagtgtatca gtcgaggat aataatgggt 2400
catcaactta ggcaactggg tgaagtgcac aaataaaagg aacaaaata atctcaaca 2460
gtcaaaagat ttccactaat tagtgcact gtggtggatt aaaagatacc tattctgtg 2520
ata 2523

```

&lt;210&gt; SEQ ID NO 2

&lt;211&gt; LENGTH: 766

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 2

```

Met Ile His Asn Tyr Met Glu His Leu Glu Arg Thr Lys Leu His Gln
1             5             10             15

```

```

Leu Ser Gly Ser Asp Gln Leu Glu Ser Thr Ala His Ser Arg Ile Arg
20             25             30

```

```

Lys Glu Arg Pro Ile Ser Leu Gly Ile Phe Pro Leu Pro Ala Gly Asp

```

-continued

35					40					45					
Gly	Leu	Leu	Thr	Pro	Asp	Ala	Gln	Lys	Gly	Gly	Glu	Thr	Pro	Gly	Ser
50						55					60				
Glu	Gln	Trp	Lys	Phe	Gln	Glu	Leu	Ser	Gln	Pro	Arg	Ser	His	Thr	Ser
65					70					75					80
Leu	Lys	Asp	Glu	Leu	Ser	Asp	Val	Ser	Gln	Gly	Gly	Ser	Lys	Ala	Thr
				85					90					95	
Thr	Pro	Ala	Ser	Thr	Ala	Asn	Ser	Asp	Val	Ala	Thr	Ile	Pro	Thr	Asp
			100					105						110	
Thr	Pro	Leu	Lys	Glu	Glu	Asn	Glu	Gly	Phe	Val	Lys	Val	Thr	Asp	Ala
		115					120					125			
Pro	Asn	Lys	Ser	Glu	Ile	Ser	Lys	His	Ile	Glu	Val	Gln	Val	Ala	Gln
130						135					140				
Glu	Thr	Arg	Asn	Val	Ser	Thr	Gly	Ser	Ala	Glu	Asn	Glu	Glu	Lys	Ser
145				150						155					160
Glu	Val	Gln	Ala	Ile	Ile	Glu	Ser	Thr	Pro	Glu	Leu	Asp	Met	Asp	Lys
				165					170					175	
Asp	Leu	Ser	Gly	Tyr	Lys	Gly	Ser	Ser	Thr	Pro	Thr	Lys	Gly	Ile	Glu
			180					185						190	
Asn	Lys	Ala	Phe	Asp	Arg	Asn	Thr	Glu	Ser	Leu	Phe	Glu	Glu	Leu	Ser
		195					200					205			
Ser	Ala	Gly	Ser	Gly	Leu	Ile	Gly	Asp	Val	Asp	Glu	Gly	Ala	Asp	Leu
210						215					220				
Leu	Gly	Met	Gly	Arg	Glu	Val	Glu	Asn	Leu	Ile	Leu	Glu	Asn	Thr	Gln
225					230					235					240
Leu	Leu	Glu	Thr	Lys	Asn	Ala	Leu	Asn	Ile	Val	Lys	Asn	Asp	Leu	Ile
				245					250					255	
Ala	Lys	Val	Asp	Glu	Leu	Thr	Cys	Glu	Lys	Asp	Val	Leu	Gln	Gly	Glu
			260					265						270	
Leu	Glu	Ala	Val	Lys	Gln	Ala	Lys	Leu	Lys	Leu	Glu	Glu	Lys	Asn	Arg
		275					280						285		
Glu	Leu	Glu	Glu	Glu	Leu	Arg	Lys	Ala	Arg	Ala	Glu	Ala	Glu	Asp	Ala
290						295					300				
Arg	Gln	Lys	Ala	Lys	Asp	Asp	Asp	Asp	Ser	Asp	Ile	Pro	Thr	Ala	Gln
305					310					315					320
Arg	Lys	Arg	Phe	Thr	Arg	Val	Glu	Met	Ala	Arg	Val	Leu	Met	Glu	Arg
				325					330					335	
Asn	Gln	Tyr	Lys	Glu	Arg	Leu	Met	Glu	Leu	Gln	Glu	Ala	Val	Arg	Trp
			340					345						350	
Thr	Glu	Met	Ile	Arg	Ala	Ser	Arg	Glu	Asn	Pro	Ala	Met	Gln	Glu	Lys
		355					360						365		
Lys	Arg	Ser	Ser	Ile	Trp	Gln	Phe	Phe	Ser	Arg	Leu	Phe	Ser	Ser	Ser
370					375						380				
Ser	Asn	Thr	Thr	Lys	Lys	Pro	Glu	Pro	Pro	Val	Asn	Leu	Lys	Tyr	Asn
385					390					395					400
Ala	Pro	Thr	Ser	His	Val	Thr	Pro	Ser	Val	Lys	Lys	Arg	Ser	Ser	Thr
				405					410					415	
Leu	Ser	Gln	Leu	Pro	Gly	Asp	Lys	Ser	Lys	Ala	Phe	Asp	Phe	Leu	Ser
			420					425					430		
Glu	Glu	Thr	Glu	Ala	Ser	Leu	Ala	Ser	Arg	Arg	Glu	Gln	Lys	Arg	Glu
			435				440							445	

-continued

---

Gln Tyr Arg Gln Val Lys Ala His Val Gln Lys Glu Asp Gly Arg Val  
 450 455 460

Gln Ala Phe Gly Trp Ser Leu Pro Gln Lys Tyr Lys Gln Val Thr Asn  
 465 470 475 480

Gly Gln Gly Glu Asn Lys Met Lys Asn Leu Pro Val Pro Val Tyr Leu  
 485 490 495

Arg Pro Leu Asp Lys Lys Asp Thr Ser Met Lys Leu Trp Cys Ala Val  
 500 505 510

Gly Val Asn Leu Ser Gly Gly Lys Thr Arg Asp Gly Gly Ser Val Val  
 515 520 525

Gly Ala Ser Val Phe Tyr Lys Asp Val Ala Gly Leu Asp Thr Glu Gly  
 530 535 540

Ser Lys Gln Arg Ser Ala Ser Gln Ser Ser Leu Asp Lys Leu Asp Gln  
 545 550 555 560

Glu Leu Lys Glu Gln Gln Lys Glu Leu Lys Asn Gln Glu Glu Leu Ser  
 565 570 575

Ser Leu Val Trp Ile Cys Thr Ser Thr His Ser Ala Thr Lys Val Leu  
 580 585 590

Ile Ile Asp Ala Val Gln Pro Gly Asn Ile Leu Asp Ser Phe Thr Val  
 595 600 605

Cys Asn Ser His Val Leu Cys Ile Ala Ser Val Pro Gly Ala Arg Glu  
 610 615 620

Thr Asp Tyr Pro Ala Gly Glu Asp Leu Ser Glu Ser Gly Gln Val Asp  
 625 630 635 640

Lys Ala Ser Leu Cys Gly Ser Met Thr Ser Asn Ser Ser Ala Glu Thr  
 645 650 655

Asp Ser Leu Leu Gly Gly Ile Thr Val Val Gly Cys Ser Ala Glu Gly  
 660 665 670

Val Thr Gly Ala Ala Thr Ser Pro Ser Thr Asn Gly Ala Ser Pro Val  
 675 680 685

Met Asp Lys Pro Pro Glu Met Glu Ala Glu Asn Ser Glu Val Asp Glu  
 690 695 700

Asn Val Pro Thr Ala Glu Glu Ala Thr Glu Ala Thr Glu Gly Asn Ala  
 705 710 715 720

Gly Ser Ala Glu Asp Thr Val Asp Ile Ser Gln Thr Gly Val Tyr Thr  
 725 730 735

Glu His Val Phe Thr Asp Pro Leu Gly Val Gln Ile Pro Glu Asp Leu  
 740 745 750

Ser Pro Val Tyr Gln Ser Arg Tyr Asn Asn Gly Ser Ser Thr  
 755 760 765

---

1. An antibody having specificity for a polypeptide comprising an amino acid sequence of SEQ ID No:2 or an isoform thereof or a polypeptide comprising SEQ ID NO:2.

2. An antibody as claimed in claim 1 wherein the antibody is a monoclonal antibody, polyclonal antibody, humanised or recombinant antibody.

3. An antibody fragment having specificity for a polypeptide consisting of SEQ ID No:2 or an isoform thereof or a polypeptide comprising SEQ ID NO:2.

4. A single chain of the antibody fragment of claim 3.

5. An antibody as claimed in claims 1 to 4 wherein the antibody is an IgG antibody or IgM antibody.

6. A kit for detection of cancer in a biological sample of a subject suspected of or suffering from cancer, comprising polypeptide sequence bearing SEQ ID NO:2 or an isoform thereof or a polypeptide comprising SEQ ID NO:2 optionally coupled to a solid matrix and instructional material.

7. A kit as claimed in claim 6 wherein the solid matrix comprises nitrocellulose paper, glass slide, microtitre plates and wells.

8. A kit for detection of cancer in a biological sample of a subject suspected of or suffering from cancer comprising an antibody or a fragment thereof as claimed in claims 1 and 3.

**9.** A kit as claimed in claim **8** wherein the antibody is a labelled antibody.

**10.** A method for detecting a cancer in a subject suffering from or suspected of suffering from a cancer, comprising the steps of:

providing a biological sample of a subject suspected of cancer; and

detecting the presence of an antibody generated against SEQ ID NO:2 or an isoform thereof or a polypeptide comprising SEQ ID NO:2,

the presence of said antibodies being indicative of cancer.

**11.** A method for detecting a cancer in a subject suffering from or suspected of suffering from a cancer, comprising the steps of:

providing a biological sample of a subject suspected of cancer; and

detecting the presence of polypeptide of SEQ ID NO:2 or an isoform or a polypeptide sequence comprising SEQ ID NO:2 therein.

**12.** A method for detecting a cancer in a subject suffering from or suspected of suffering from a cancer, comprising the steps of:

providing a biological sample of a subject suspected of cancer;

contacting the sample with a kit as claimed in claim **6**

determining binding of SEQ ID NO:2 or an isoform thereof or a polypeptide sequence comprising SEQ ID NO:2 with antibody through a detectable signal which is indicative of cancer.

**13.** A method for detecting a cancer in a subject suffering from or suspected of suffering from a cancer, comprising the steps of:

providing a biological sample of a subject suspected of cancer;

contacting the sample with a kit as claimed in claim **8** and

determining the binding of SEQ ID NO:2 or an isoform thereof or a polypeptide sequence comprising SEQ ID NO:2 with antibody generated against the said polypeptide through a detectable signal which is indicative of cancer.

**14.** A kit or a method as claimed in any of the preceding claims wherein the cancer is of ectodermal, endodermal or mesodermal origin.

**15.** A kit as claimed in any of the preceding claims wherein the cancer is of lung, breast stomach, esophagus, colon, ovarian, testis, cervix, skin, prostate, oral, bladder, liver, endometrial, kidney, brain, blood, vulva, vagina, gall bladder, eye and bone cancer.

**16.** A method as claimed in any of claim **10**, **11**, **12** or **13** wherein the subject is a mammal.

**17.** An anti-SEQ ID No:2 antibody, an antibody and antigen detection kit and a method for detection of cancer substantially as herein described and illustrated.

\* \* \* \* \*

专利名称(译)	新型癌症相关抗体及其在癌症诊断中的应用		
公开(公告)号	<a href="#">US20100221742A1</a>	公开(公告)日	2010-09-02
申请号	US12/705117	申请日	2010-02-12
申请(专利权)人(译)	国家免疫学研究所		
当前申请(专利权)人(译)	国家免疫学研究所		
[标]发明人	SURI ANIL KUMAR		
发明人	SURI, ANIL KUMAR		
IPC分类号	G01N33/53 C07K16/32		
CPC分类号	G01N33/574 C07K16/3069 A61P35/00		
优先权	1945DEL2004 2004-10-07 IN 11/664881 2007-10-30 US PCT/IB2005/002972 2005-10-07 WO		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

摘要(译)

本发明涉及对包含SEQ ID No : 2的氨基酸序列或其同种型或包含SEQ ID NO : 2的多肽的多肽具有特异性的抗体。

Figure 1




Figure 2

